Skip to main contentAll experts

DrMarc Zumberg

CLIN PROF

MD-MEDICINE

Orcid identifier0000-0002-9552-475X (opens in a new tab)⁠
  • CLIN PROF
    MD-MEDICINE

GRANTS

  • GRANT
    A Phase 2b, multicenter, randomized, double-blind study of safety and efficacy of TAK-755 (rADAMTS13) with minimal to no plasma exchange (PEX) in the treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP)
    Takeda Development Center Americas Inc14 Dec 2023 - 13 Dec 2028
    Active
  • GRANT
    Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia - PATH
    National Institute of Health Nhlbi2 Aug 2021 - 28 Feb 2023
    Expired
  • GRANT
    Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia - PATH
    National Institute of Health Nhlbi2 Aug 2021 - 29 Feb 2024
    Expired